98%
921
2 minutes
20
Computational medicine promises significant advancements in healthcare, using physics-based simulations and artificial intelligence to optimise disease diagnosis, personalise treatment strategies and accelerate medical innovation. Biomedical research efforts are generating a growing number of computational models of human pathophysiology and medical treatments, with advanced applications in areas such as cardiovascular diseases, orthopaedics and cancer diagnosis. However, the widespread adoption of these models is hindered by technological and regulatory barriers. This article provides an overview of the potential impact, needs and challenges of the adoption of in silico medicine in the healthcare ecosystem, with a focus on initiatives to sustain this technology within the European Union's regulatory environment. The article introduces the concept of the 'computational model lifecycle' as a framework to describe the stages from academic research to pre-clinical and clinical applications, analysing key opportunities and challenges in translating these technologies at each stage. These challenges are associated with data management, standards for model credibility assessment, transparency of regulatory frameworks, and clinical integration. The article highlights European initiatives such as the European Health Data Space and the Virtual Human Twins Initiative, aimed at fostering the development and application of computational medicine in healthcare.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12402556 | PMC |
http://dx.doi.org/10.1177/00368504251344145 | DOI Listing |
Protein Cell
August 2025
Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200433, China.
Cardiovascular disease (CVD) research is hindered by limited comprehensive analyses of plasma proteome across disease subtypes. Here, we systematically investigated the associations between plasma proteins and cardiovascular outcomes in 53,026 UK Biobank participants over a 14-year follow-up. Association analyses identified 3,089 significant associations involving 892 unique protein analytes across 13 CVD outcomes.
View Article and Find Full Text PDFObesity (Silver Spring)
September 2025
Division of Hematology, Oncology, and Palliative Care, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Objective: From October 18-20, 2022, the National Institutes of Health held a workshop to examine the state of the science concerning obesity interventions in adults to promote health equity. The workshop had three objectives: (1) Convene experts from key institutions and the community to identify gaps in knowledge and opportunities to address obesity, (2) generate recommendations for obesity prevention and treatment to achieve health equity, and (3) identify challenges and needs to address obesity prevalence and disparities, and develop a diverse workforce.
Methods: A three-day virtual convening.
Stroke
September 2025
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. (V.Y., B.C.V.C., L.C., L.O., M.W.P.).
Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.
Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.
Mult Scler
September 2025
Neuroimaging Unit, Neuroimmunology Division, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, VA Medical Center, TN Valley Healthcare System, Nashville, TN, USA.
Background: There is limited knowledge on the post-glymphatic structures such as the parasagittal dural (PSD) space and the arachnoid granulations (AGs) in multiple sclerosis (MS).
Objectives: To evaluate differences in volume and macromolecular content of PSD and AG between people with newly diagnosed MS (pwMS), clinically isolated syndrome (pwCIS), or radiologically isolated syndrome (pwRIS) and healthy controls (HCs) and their associations with clinical and radiological disease measures.
Methods: A total of 69 pwMS, pwCIS, pwRIS, and HCs underwent a 3.
Eur J Case Rep Intern Med
August 2025
Division of Gastroenterology, Department of Medicine, Staten Island University Hospital, Northwell Health, Staten Island, USA.
Unlabelled: Pancreatic signet ring cell carcinoma (PSRCC) is a rare and aggressive subtype of pancreatic cancer with a dismal prognosis. We present the case of a 50-year-old male who, within six weeks, developed a pancreatic mass with liver metastases. Endoscopic ultrasound-guided biopsy confirmed PSRCC.
View Article and Find Full Text PDF